Explore

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Radiopharmaceutical Development Accelerates, Demanding Evolved Preclinical Strategies

Harvard Medical School Study Highlights Environmental Factors in Disease Risk

Harvard Medical School Study Highlights Environmental Factors in Disease Risk

A team of scientists at Harvard Medical School has conducted a large-scale study to explore the impact of environmental exposures on health outcomes. The research, published in Nature Medicine, analyzed over 100,000 associations between various exposures and health outcomes using data from the National Health and Nutrition Examination Survey. The study found that while individual exposures have a moderate impact, their cumulative effect can be as significant as genetic factors in determining disease risk. The research emphasizes the importance of considering multiple exposures simultaneously to better understand their collective impact on health.

Dr. Ulrich Steidl Appointed Director of Montefiore Einstein Comprehensive Cancer Center, Enhancing Cancer Research Leadership

Dr. Ulrich Steidl Appointed Director of Montefiore Einstein Comprehensive Cancer Center, Enhancing Cancer Research Leadership

Dr. Ulrich Steidl has been appointed as the director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and vice president of cancer medicine at Montefiore Einstein. This appointment marks a significant leadership change for the National Cancer Institute-designated center located in the Bronx, New York. Dr. Steidl, who has been with the institution since 2008, has played a pivotal role in advancing translational research and clinical applications in cancer treatment. His research focuses on the biology of blood cancers, particularly the characterization of pre-leukemic stem cells and their progression to leukemic stem cells. Dr. Steidl's work has been instrumental in understanding myelodysplastic syndrome (MDS) and its evolution into acute myeloid leukemia (AML), offering new therapeutic targets. His leadership is expected to further MECCC's mission of integrating scientific excellence with community-centered cancer care.

bioAffinity Technologies' CyPath® Lung Test to Feature at Cleveland Clinic Symposium

bioAffinity Technologies' CyPath® Lung Test to Feature at Cleveland Clinic Symposium

bioAffinity Technologies, Inc. will present its CyPath® Lung test at the Cleveland Clinic's annual 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. The test, which is noninvasive and uses advanced flow cytometry and artificial intelligence, is designed to aid in the early detection of lung cancer in high-risk patients. The symposium will gather global leaders in lung cancer research to discuss emerging diagnostic technologies and the changing epidemiology of lung cancer. Dr. Gordon Downie, bioAffinity's Chief Medical Officer, will participate in a panel on lung nodule management, highlighting the benefits of CyPath® Lung in clinical decision-making and its potential to reduce unnecessary invasive procedures.

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

MSU Researchers Analyze Disparities in U.S. Cancer Mortality Decline

MSU Researchers Analyze Disparities in U.S. Cancer Mortality Decline

Researchers at Mississippi State University's Social Science Research Center, in collaboration with Oak Ridge National Laboratory, have conducted a study on the decline in cancer mortality rates across the U.S. The study, published in the British Journal of Cancer, analyzed data from nearly 3,000 counties between 1981 and 2019. It found that urban and affluent areas experienced more significant declines in cancer deaths compared to rural and less affluent regions. The research highlights the uneven distribution of health improvements and suggests that socioeconomic factors and local health practices play a crucial role in these disparities.

St. Jude Identifies PHIP as Key Target in SWI/SNF-Mutant Cancers

St. Jude Identifies PHIP as Key Target in SWI/SNF-Mutant Cancers

Researchers at St. Jude Children’s Research Hospital have identified the gene-regulatory protein PHIP as a critical vulnerability in cancers driven by SWI/SNF mutations. These mutations, affecting the chromatin-remodeling complex, are present in about one in four cancers. The study, published in Nature Communications, highlights PHIP as a potential therapeutic target for hard-to-treat cancers, including rhabdoid tumors in children. The research used cell line and patient-derived models to demonstrate how PHIP supports cancer growth by cooperating with SWI/SNF to activate transcription and suppress the opposing NuRD complex.

Harvard Study Highlights Importance of Exposome in Health Outcomes

Harvard Study Highlights Importance of Exposome in Health Outcomes

Researchers from Harvard Medical School have conducted a large-scale study examining the exposome, which encompasses all environmental exposures a person experiences throughout their life. The study analyzed over 100,000 associations between various exposures and health outcomes, revealing that while individual exposures have moderate effects, their cumulative impact can be as significant as genetic factors. The findings emphasize the need for comprehensive research on environmental risks to better understand their role in health and disease.

Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Research Highlights Impact of Insurance on Cancer Survival Among Young Adults

Recent research underscores the significant role that insurance status plays in cancer survival rates among young adults in the United States. A comprehensive review of scientific literature, involving nearly 470,000 Americans aged 15 to 39 diagnosed with cancer, reveals that those with private health insurance have a survival advantage over those on Medicaid or without insurance. This advantage varies by cancer type, with private insurance reducing the risk of death by 8% for lymphoma and up to 2.5 times for melanoma and other cancers. The study highlights the instability of health coverage for young adults, who often lose insurance when they turn 26 or start jobs without benefits, leaving many uninsured or underinsured. This instability exacerbates the already slower improvements in cancer survival rates for this age group compared to children and older adults.

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

Insurance Status Identified as Key Factor in Cancer Survival Rates Among Young Adults

Insurance Status Identified as Key Factor in Cancer Survival Rates Among Young Adults

A recent analysis of nearly 470,000 young Americans diagnosed with cancer reveals that insurance status significantly impacts survival rates. The study found that young adults with private insurance have better survival outcomes compared to those on Medicaid or uninsured. This disparity is attributed to differences in access to specialists, timely treatment, and eligibility for clinical trials. The research highlights the instability of health coverage among young adults, who often face gaps in insurance due to life transitions such as finishing school or starting new jobs.

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast